WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Scientific herding improves yield, environmentThrifty Asian Games puts spring in the step of rural studentsRenowned Berliner Philharmoniker to perform at Shanghai's art festivalHighlights of beach volleyball match at 19th Asian GamesVolleyball ignites latest rural sports passion on China's tropical islandSpringtime blossoms add cheer to tourismInt'l photo festival brings fusion of tradition and modernity to China townInt'l plum blossom festival kicks off in NanjingChina issues guidelines to enhance management of community workersShanghai holds int'l poetry festival
3.7679s , 6497.4140625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Circuit news portal